Wegovy could be covered for at least 3.6M people under new Medicare rules

Cost, Coverage, and Medicare Negotiation

• Wegovy is ~$10k/year in the US; several commenters argue it may still be cost‑effective if it prevents expensive outcomes (heart attacks, strokes, diabetes, surgery).
• Others worry about massive taxpayer outlays and higher insurance premiums if it becomes a “forever” drug.
• Discussion notes new Medicare powers to negotiate Part D drug prices; many expect Wegovy to be targeted, potentially lowering costs.
• Comparisons are made to other expensive preventives (e.g., HIV PrEP) that are cheaper than treating the resulting disease.

Long‑Term Safety and Effectiveness

• Some are optimistic, citing two decades of GLP‑1 agonist use for diabetes and no obvious “fen‑phen‑style” catastrophe so far.
• Others emphasize that large‑scale, long‑duration weight‑loss use is newer, so long‑term side effects, GI issues, muscle loss, and senior fall risk are still uncertain.
• Concern about whether patients must stay on it indefinitely; unclear evidence in the thread on durable weight loss after stopping.

Root Causes vs. Pharmaceutical Fix

• Strong debate over whether drugs address the “root cause” of obesity.
  • One side: appetite‑suppressing drugs directly target the physiological driver (excess intake) and are among the only reliably effective tools besides bariatric surgery.
  • Other side: root causes lie in food environment, ultra‑processed foods, marketing, portion sizes, sedentary life, and socioeconomics; drugs are a palliative that leaves those systems untouched.
• Many argue for regulation similar to tobacco: taxes on sugary/processed foods, limiting marketing (especially to kids), ending subsidies for unhealthy ingredients, addressing food deserts, and better nutrition education.
• Others are pessimistic these systemic measures will ever be implemented at scale, making drugs a pragmatic necessity.

Equity, Pricing, and International Differences

• US prices are far higher than in the UK/EU; some say Americans effectively cross‑subsidize global R&D, others dispute “below cost” claims but agree US pricing power and regulation are key drivers.
• Ethical tension: some propose conditioning coverage on lifestyle efforts (e.g., step counts), while others argue obesity is already driving high costs, and gatekeeping is both unethical and economically shortsighted.

Broader Impacts and Alternatives

• Some see GLP‑1 drugs and related gene therapies as transformative for obesity, diabetes, cardiovascular risk, and even addiction.
• There is concern about cosmetic or mild-use “abuse” and about perverse incentives for pharma and intermediaries (e.g., compounding pharmacies profiting from shortages).